# Evaluation of XYA02 in Patients With Advanced Solid Tumors

> **NCT07670312** · PHASE1,PHASE2 · RECRUITING · sponsor: **XYone Therapeutics, Inc** · enrollment: 190 (estimated)

## Conditions studied

- MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- GEJ Adenocarcinoma
- Colorectal Cancer
- Pancreatic Adenocarcinoma
- Gastric Cancer

## Interventions

- **BIOLOGICAL:** XYA02

## Key facts

- **NCT ID:** NCT07670312
- **Lead sponsor:** XYone Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-17
- **Primary completion:** 2029-09-15
- **Final completion:** 2030-09-15
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2026-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670312, "Evaluation of XYA02 in Patients With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07670312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*